SUNation Energy Announces 2025 Third Quarter Results and Reiterates 2025 Full Year Financial Guidance GlobeNewswire November 10, 2025 Q3 2025 Select Highlights Sales Increased 29% to $19.0 Million Gross Profit Rose to $7.2 Million; Gross Margin Improved to 38% Net Loss Narrowed to $0.4 Million Adjusted EBITDA Improved to $898,000 Unrestricted Cash Rose to $5.4 […]

Surgery Partners, Inc. Announces Third Quarter 2025 Results GlobeNewswire November 10, 2025 BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights (All comparisons

Pixalate's October 2025 United States Publisher Rankings: Top Mobile 'Sports' Apps For Programmatic Advertising Traffic Quality in the Apple App Store and Google Play Store GlobeNewswire November 10, 2025 According to Pixalate's October 2025 rankings, 'CBS Sports Fantasy', 'ESPN: Live Sports & Scores, and 'FotMob – Soccer Live Scores' were the top three Apple App

FG Nexus to Present at the 2025 Cantor Crypto & AI/Energy Infrastructure Conference GlobeNewswire November 10, 2025 Charlotte, NC, Nov. 10, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”), today announced that management will participate at the Cantor Crypto & AI/Energy Infrastructure Conference on November 10-12th, 2025 at the

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) GlobeNewswire November 10, 2025 Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern In HS, over 4 weeks of therapy,

Bakkt Reports Third Quarter 2025 Results GlobeNewswire November 10, 2025 – GAAP revenue1 of $402.2 million, up 27% year-over-year– GAAP net loss of $23.2 million, primarily due to 2024 registered direct offering warrant liability mark-to-market– Adjusted EBITDA of $28.7 million, up 241% year-over-year– Ended the quarter with $64.4 million in cash and restricted cash with

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 10, 2025 Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer GlobeNewswire November 10, 2025 Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives Investors, stakeholders, analysts and

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships GlobeNewswire November 10, 2025 Company focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization. Patient enrollment in SYMON-II clinical trial now approximately 50% completed. Recent private placement transaction completed in October 2025; Company continues

Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 10, 2025 Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC Data from a Phase 1b expansion cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in 1L HPV-negative R/M HNSCC